INTRODUCTION
Abs have emerged as an important class of therapeutics for the treatment of various diseases, including cancer 1, 2 . Numerous Abs are already in use and many more are currently under development. Abs can easily be obtained from different sources; for example, Abs can be derived from patients themselves, from synthetic combinatorial libraries or from humanized chimeric Abs, all of which can be used in humans. Notably, one common feature of Abs is that they are highly specific to a single target and, because of their clonal nature, a different Ab is required for each target. We have devised a new approach in which we modify the binding sites of a single Ab, 38C2, allowing it to be retargeted to more than one receptor [3] [4] [5] [6] [7] . Such Ab constructs are useful for adapter immunotherapy.
Ab 38C2 possesses a pair of reactive Lys residues 8 in its binding sites that allow it to covalently react with a compound equipped with a diketone or vinylketone function. A diketone compound reacts with the reactive Lys residues in the Ab 38C2 binding sites forming a Schiff base, which isomerizes to the more stable enaminone derivative (Fig. 1a) . Similarly a vinylketone compound reacts with the Lys residues in the binding sites affording the corresponding Michael-type adducts (Fig. 1b) . Therefore, the non-targeting catalytic Ab 38C2 could be selectively modified in its binding sites using a small-molecule inhibitor of the cellsurface receptors, and the resultant 38C2 constructs or the chemically programmed 38C2 (cp38C2) would function like a cell-targeting Ab.
Indeed, numerous antagonists of a v b 3 and a v b 5 integrins, which are equipped with a diketone (e.g., 1) or an acetone aldol adduct of a vinylketone linker (e.g., 2), reacted selectively with 38C2 in its binding sites to produce the cell-targeting cp38C2 when treated with B0.5 equiv. 38C2 (Fig. 2) 4, 7 . In the latter case, an aldol linker was used as a prolinker (i.e., an acetone aldol adduct of the vinylketone), because the vinylketone linker was highly reactive. Ab 38C2 catalyzed the retro-aldol reaction of the prolinker to give free vinylketone linker, which then underwent Michael addition, in situ, with the reactive Lys residues in the Ab binding sites. An analogous construct formation or chemical programming was also realized using the humanized Ab 38C2, and the a v b 3 -and a v b 5 -targeting antagonist diketone 9 .
Retargeting of an Ab has also been achieved by conjugating the targeting agents to the Fc region in a conventional manner. Their effect can be similar; however, unlike the diketone or vinylketone strategy, a conventional conjugate is not homogenous 10 . In another example, an Ab can be retargeted using a targeting agent-hapten conjugate, against which the Ab has been elicited without forming a formal conjugate 11 . A comparative study of these conjugates is needed to determine the advantages and limitations of one approach compared with the others.
The above-mentioned cp38C2 constructs bound strongly to integrins a v b 3 -and a v b 5 -expressing cancer cells, such as human Kaposi's Sarcoma (SLK), human melanoma (M21) and human breast carcinoma (MDA-MB-231 and MDA-MB-435) [3] [4] [5] 7 . The constructs inhibited the growth of the primary tumor and/or metastases of these human cancers as well as several others, such as human colon cancer (SW1222), which lack expression of a v b 3 . Mechanistically, the a v b 3 -and a v b 5 -integrin-targeting 38C2 constructs caused toxicity to cells not only by antagonizing the integrins or causing antiangiogenic effects, but also by instigating Ab-dependent cellular and complement-mediated cytotoxicities 5 .
Experimental design
For the formation of Ab 38C2 constructs, we prepared numerous a v b 3 -and a v b 5 -integrin-targeting molecules possessing a linker arm, and converted them to their diketone or provinylketone derivatives. However, a detailed protocol for the syntheses of all these compounds is beyond the scope of this article (one should refer to the original publications) 4, 7 . Here, we provide methods for the transformation of a representative a v b 3 -and a v b 5 -targeting molecule possessing a linker arm to its diketone or provinylketone derivatives, for conjugate formation of the latter with Ab 38C2 and for analysis of the resultant constructs. Specifically, the following are described: syntheses of compounds 1 and 2 starting from the antagonist derivative 3a, and acids 7 and 9 (Fig. 3) ; a method for the formation of cp38C2 using 38C2 and 1 or 2; and characterization of the resultant constructs using a fluorescence assay. . Compound 3a was conjugated to the diketone or provinylketone linker (7 or 9) as shown in Figure 3 . Thus, the Boc-protecting group in compound 3a was deprotected using trifluoroacetic acid (TFA) to give compound 6 in the form of its TFA salt. Separately, acids 7 and 9 were activated using Nhydroxysuccinimide (NHS) and 1-[3-dimethylaminopropyl]-3-ethylcarbodiimide hydrochloride (EDC) to give the corresponding NHS esters, 8 and 10, which were reacted with compound 6 under basic conditions to afford compounds 1 and 2, respectively. Products were purified by silica column chromatography using a mixture of methanol-dichloromethane (MeOH-CH 2 Cl 2 ) with increasing concentrations of MeOH (5-20%). The purified small molecules equipped with these linkers were ready for conjugation with 38C2. For the construct formation, Ab 38C2 (1 equiv.) was treated with compound 1 (2 equiv.) or 2 (2.5 equiv.) for 0.5-24 h at room temperature (23 1C) or 37 1C to give the corresponding 38C2 constructs, which could be used without additional treatments.
Analysis of cp38C2 constructs
Formation of the Ab constructs is mainly analyzed by determining their catalytic activities using methodol as a substrate 13 . As both Lys residues of 38C2 are blocked by the diketone or vinylketone compounds in 38C2 constructs, the latter are non-catalytic and do not catalyze the retro-aldol reaction of methodol, 11. By contrast, it is efficiently converted to the corresponding aldehyde, 12, using a catalytic amount of 38C2. The formation of 12 can be quantified using a fluorometer. The catalytic activity of 38C2 constructs, 38C2-1 and 38C2-2, is determined using a 96-well plate that can be used with a microplate spectrofluorometer, and compared with Ab 38C2 as a positive control or buffer as a negative control. An abbreviated method is included in the procedure, and the results obtained are shown in Figure 4 . Thus, the production of aldehyde 12 from 11 (200 mM) using catalytic Ab 38C2 (1 mM) is evident from the increase in fluorescence with time. By contrast, the reaction of 11 with 38C2-1 or 38C2-2 conjugates did not show an increase in fluorescence, thereby confirming the conjugate formation. These experiments have been repeated numerous times without contradictory results. Therefore, a single experiment is enough to confirm the noncatalytic activity of 38C2 conjugates. It is, however, advisable to carry out this experiment twice before making a decision about the conjugate formation when these studies are performed for the first time.
Confirmation of the conjugate formation between 38C2 and compounds 1 or 2 can also be established using matrix-assisted laser desorption/ionization (MALDI) spectrometry, similar to that previously reported using 38C2 Fab, and analogs of compounds 1 and 2 (ref. 4). In these spectra, an increase of approximately twice the molecular weight of the diketone or vinylketone compounds to that of Ab 38C2 was noted. As an example, Figure 5 shows mass spectra of Ab 38C2 (weight-averaged molecular mass (M w ) ¼ 150,951) and cp38C2-2 (M w ¼ 153,513) obtained from the reaction of 38C2 with compound 2. The conjugate formation was also established by ELISA experiments, and by flow cytometry to record the binding to cells expressing integrins a v b 3 and a v b 5 . These methods are described elsewhere [3] [4] [5] 7, 9 .
Note regarding reagents All common solvents for the syntheses of compounds 1, 2 and their precursors were obtained from Fishers' Scientific or SigmaAldrich. Methylene chloride was dried over CaH 2 , and benzene was dried over Na and distilled. Figure 4 | Catalytic activity of 38C2 constructs, 38C2-1 (prepared from compound 1) and 38C2-2 (prepared from compound 2) compared with unmodified 38C2 and buffer alone. 38C2 and its constructs were used at a concentration of 1 mM and methodol was used at 200 mM. Progress of the retro-aldol reaction of methodol to produce 6-methoxynaphthaldehyde was monitored using a spectrofluorometer. The x-axis shows the time after methodol addition and the y-axis represents the raw fluorescence data. REAGENT SETUP Compounds 3a, 7 and 9 The synthesis of compound 3a using acid 4 and amine 5 is described in ref. 7 and the synthesis of compound 9 is described in ref. 4 ; for convenience, they are also shown in Figure 6 . For the detailed processes, investigators should consult the original papers. If requested, the processes and small amounts of compounds 1, 2, 3a, 7 and 9 will also be made available. EQUIPMENT SETUP Analysis of cp38C2 constructs This requires a microplate spectrophotometer equipped with a computer running the SOFTmax Pro 2.6.1 application, and a 96-well plate compatible with the fluorescence reader.
PROCEDURE
Conversion of compound 3a to 6 1| Dry a 10-ml single-neck round-bottomed flask containing a Teflon-coated magnetic stir bar in an oven at 150 1C.
2| Take the flask out of the oven, cap it with a rubber septum and insert a nitrogen inlet with a fairly strong nitrogen flow and a vent using disposable syringe needles. Allow the flask to cool to 23 1C.
3| Add compound 3a (200 mg, 0.24 mmol) to the flask, cap with a rubber septum and insert a nitrogen inlet with a disposable syringe needle.
4| Add 2 ml dry CH 2 Cl 2 to the flask using a plastic syringe fitted with a 20-gauge hypodermic needle, and turn the magnetic stirrer on. 5| Add 0.5 ml anisole and 0.5 ml TFA (slowly over 1 min) sequentially to the flask using a plastic syringe fitted with a 20-gauge hypodermic needle. ! CAUTION TFA is corrosive (see material safety data sheet at http://www.sigmaaldrich.com/catalog/search/ProductDetail/ SIAL/302031).
6|
Continue stirring for 16 h at 23 1C and check the completion of the reaction using thin-layer silica gel plates and CH 2 Cl 2 /MeOH (9:1; retention factor (R f ) ¼ 0.5 for 3a and 0.2 for 6).
7| After completion of the reaction, turn the stirrer off, and remove the nitrogen inlet and the rubber septum.
8| Take the magnetic stir bar out, wash it with CH 2 Cl 2 (1 ml) into the flask, and evaporate solvents under reduced pressure on a rotary evaporator keeping the bath temperature o30 1C.
9| Add 5 ml ethyl acetate (EtOAc) and evaporate solutions using the rotary evaporator as described in Step 8. Repeat the process twice to remove TFA.
10| Dry the yellow residue using a vacuum pump (o1 mm Hg) overnight to give key intermediate 6 as a TFA salt. This product can be used to prepare 1 and 2 without purification. ' PAUSE POINT Compound 6 . TFA is freshly prepared from 3a when needed, and can be kept overnight at -20 1C.
Syntheses of NHS esters 8 and 10 11| Dry a 25-ml single-neck round-bottomed flask containing a Teflon-coated magnetic stir bar in an oven at 150 1C.
12| Take the flask out of the oven and cap it with a rubber septum. Insert a nitrogen inlet with a fairly strong nitrogen flow and a vent using disposable syringe needles. Allow the flask to cool to 23 1C.
13| Weigh 415 mg compound 7 (1.3 mmol, 1.0 equiv.) or 450 mg compound 9 (1.3 mmol, 1.0 equiv.) into the flask, and recap with the septum attached to the nitrogen inlet.
14| Transfer 5 ml dry CH 2 Cl 2 into the flask using a plastic syringe fitted with a 20-gauge hypodermic needle, and turn the magnetic stirrer on. 16| Recap the flask with the septum attached to the nitrogen inlet, and continue stirring for 4 h at 23 1C.
17|
Monitor the reaction by TLC using thin-layer silica gel plates (solvent system: EtOAc/hexanes, 4:1; R f ¼ 0.70 for compound 8 and R f ¼ 0.55 for 10).
18| Remove the septum and nitrogen inlet after the reaction has completed (4 h).
19| Remove the solvent under reduced pressure on a rotary evaporator to obtain the crude residue keeping the bath temperature o40 1C.
20| Pack a chromatographic column (2.5 cm i.d. Â 15.5 cm length) with B45 g dry silica gel and cover the top of the column further with a layer of sand (B1 cm thick). Equilibrate the column with hexanes.
21| Dissolve the residue from
Step 19 in CH 2 Cl 2 , and load the solution on the top of the silica column using a pipette.
22| Elute the column with EtOAc/hexanes (20, 50, 80 and 100%; 200 ml each) under minimal air pressure and collect the fractions (10 ml each) using test tubes.
23| Identify the fractions containing the desired products by TLC using silica gel plates and 80% EtOAc/hexanes (R f ¼ 0.70 for 8 and 0.55 for 10). Collect all fractions showing the desired compounds into a round-bottomed flask. m CRITICAL STEP NHS esters are susceptible to hydrolysis. It is advisable to perform the chromatography in one continuous step -do not let the compounds sit on the silica gel for a prolonged period.
24| Remove the solvents under reduced pressure on a rotary evaporator, and dry the residue using a high-vacuum pump (o1 mm Hg) to give pure product 8 (typical yield: 430 mg, 80%) or 10 (typical yield: 450 mg, 78%). ' PAUSE POINT Compounds 8 and 10 can be stored at -20 1C under argon and dry conditions for several weeks; however, it is advisable to prepare them fresh and use as soon as possible for the best results. 26| Cap the flask with a rubber septum. Insert a nitrogen inlet with a disposable syringe needle.
27| Add 2 ml CH 3 CN to the flask and turn the magnetic stirrer on.
28| Add 0.25 ml TEA to the reaction mixture.
29| Weigh out 150 mg NHS ester 8 (0.36 mmol, 1.5 equiv.) for compound 1 or 160 mg NHS ester 10 (0.36 mmol, 1.5 equiv.) for compound 2 in a separate vial, dissolve it in CH 3 CN (1 ml) and add it into the reaction mixture using a plastic syringe fitted with a 20-gauge hypodermic needle.
30|
Continue stirring for 4 h at 23 1C, turn the stirrer off and remove the nitrogen inlet and rubber septum.
31| Dilute the reaction mixture with 30 ml EtOAc, and transfer the mixture to a separatory funnel.
32| Wash the organic layer with a 1:1 (vol/vol) mixture of 10% citric acid and brine (5 ml each), and dry the organic layer with anhydrous Na 2 SO 4 (5-10 g).
33|
Filter the mixture under gravity through a fluted filter paper on a glass filter funnel and collect the filtrate in a round-bottomed flask.
34| Remove the solvent under reduced pressure on a rotary evaporator to get the crude residue.
35| Pack a chromatography column with silica gel and cover the top of the column further with a layer of sand (B1 cm thick). Equilibrate the column with CH 2 Cl 2 .
36| Dissolve the residue from
Step 34 in CH 2 Cl 2 , and load the solution on top of the silica column using a pipette.
37| Elute the column with MeOH/CH 2 Cl 2 (0-25%) under minimal air pressure, and collect the fractions using test tubes.
38| Identify the fractions containing desired product 1 or 2 by TLC using silica gel plates and 20% MeOH/CH 2 Cl 2 (R f ¼ 0.45 for 1 and 0.37 for 2). Collect all the fractions showing 1 and 2 separately into round-bottomed flasks.
39| Remove the solvents under reduced pressure on a rotary evaporator, and dry the residue using a high-vacuum pump (o1 mm Hg) to give pure product 1 (typical yield: 167 mg, 75%) or 2 (typical yield: 181 mg, 75%). ' PAUSE POINT Compounds 1 and 2 were stored for several weeks under an argon atmosphere in a refrigerator at -20 1C with no sign of any appreciable decomposition. Stock solution of 38C2 (10 mg ml -1 , 66.7 mM solution) in PBS buffer (pH 7.4), and compounds 1 (9.3 mg ml -1 , 10 mM solution) and 2 (9.6 mg ml -1 , 10 mM solution) in CH 3 CN, can be kept at -20 1C for an extended period of time.
Formation of Ab 38C2 constructs (cp38C2s) 40| Using a micropipette, transfer 37.5 ml Ab 38C2 (10 mg ml -1 solution in PBS) solution to two separate 1.5 ml Eppendorf tubes and appropriately label. Keep the Ab solution cold using an ice bath.
41| Transfer 2 ml of the 10 mM stock solutions of compound 1 and 2 into two separate 1.5 ml Eppendorf tubes containing 18 ml of PBS buffer (pH 7.4), making the end concentration of the solutions 1 mM. Appropriately label them, and vortex. Keep the solutions cold using an ice bath.
42| Transfer 10 ml of the solution of compound 1 from Step 41 to the first Ab 38C2 solution from
Step 40, add 2.5 ml of PBS (pH 7.4) to it, and vortex. Similarly, transfer 12.5 ml of the solution of compound 2 from Step 41 to the second Ab 38C2 solution from
Step 40, and vortex.
43| Incubate the solution containing 1 for 0.5 h at room temperature (23 1C), and that containing 2 for 16 h at room temperature followed by 2 h at 37 1C.
' PAUSE POINT The incubation time can be prolonged to 16 h at room temperature (23 1C) for both solutions. However, the solution containing 2 has to be further incubated at 37 1C for 2 h to ensure the complete formation of construct 38C2-2.
Analysis of cp38C2 constructs 44| Dilute Ab 38C2 and the 38C2 constructs in PBS (pH 7.4; 1 mM solution in Ab, 100 ml each). Use an appropriate volume of the stock solution of Ab 38C2 (incubated at 37 1C for 2 h) for comparison with the solutions obtained in Step 43.
45| Start the spectrofluorometer, and set the program to read fluorescence using wavelength of excitation (l ext ) ¼ 330 nM and wavelength of emission (l em ) ¼ 452 nM. 47| Add methodol (2 ml from 10 mM stock solution) 200 mM to the four wells containing Ab, constructs and buffer, and measure the formation of 6-methoxynaphthaldehyde for 60 min starting at 0 min. A representative example is shown in Figure 4 .
48| Dilute the mixture (3.3 ml) from
Step 43 using 46.7 ml buffer, vortex to give 38C2 constructs with 3. ? TROUBLESHOOTING In general, the processes described here have been repeated numerous times and no difficulties have been noted. Nevertheless, some potential problems might arise if proper care is not taken, as illustrated by the following examples: (i) the NHS esters 8 and 10 are water sensitive, and yields of 1 and 2 might vary depending upon the quality of compounds 8 and 10; (ii) if compounds 1 and 2 are eluted with traces of silica gel, which might occur during their purification on silica gel using MeOH/CH 2 Cl 2 (0-25%) as an eluting solvent, the silica gel can be removed by dissolving the compound in 5% MeOH/CH 2 Cl 2 and filtering through a syringe filter (PTFE, 0.2 mm; Thomson Instrument Company, cat. no. TIC-6550225); (iii) if compounds 1 and 2 are not pure, construct formation between 38C2 and compounds 1 or 2 will not be efficient; (iv) amine-and thiol-containing buffer might impair the 38C2 construct formation, and should therefore be avoided. 
ANTICIPATED RESULTS

